NCT03980288View on ClinicalTrials.gov

4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 23, 2019

Primary Completion Date

December 30, 2020

Study Completion Date

December 30, 2020

Conditions
Advanced Hepatocellular Carcinoma
Interventions
DRUG

CAR-GPC3 T Cells

Pretreatment with fludarabine and cyclophosphamide CAR-GPC3 T Cells infusion

Trial Locations (1)

310006

First affiliated hospital, Zhejiang University, Hangzhou

Sponsors
All Listed Sponsors
collaborator

CARsgen Therapeutics Co., Ltd.

INDUSTRY

lead

Zhejiang University

OTHER